

PRODUCT INFORMATION




Etrasimod

Item No. 21661

CAS Registry No.: 1206123-37-6
Formal Name: (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydro-cyclopent[b]indole-3-acetic acid

Synonym: APD334
MF: C₂₆H₂₆F₃NO₃
FW: 457.5
Purity: ≥95%
UV/Vis.: λ_{max}: 227, 279 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Etrasimod is supplied as a crystalline solid. A stock solution may be made by dissolving the etrasimod in the solvent of choice, which should be purged with an inert gas. Etrasimod is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of etrasimod in these solvents is approximately 12.5 mg/ml in ethanol and approximately 30 mg/ml in DMSO and DMF.

Etrasimod is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, etrasimod should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Etrasimod has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Etrasimod is an orally bioavailable and potent antagonist of sphingosine-1-phosphate (S1P) receptors with EC₅₀ values of 0.093, 0.44, 0.32, 0.34, and 0.32 nM for human, mouse, rat, dog, and monkey S1P₁ receptors.¹ It is selective for S1P₁, S1P₄, and S1P₅ receptors with EC₅₀ values of 6.1, >10,000, >10,000, 147, and 24.4 nM for S1P₁₋₅, respectively, in a β-arrestin assay. Etrasimod (1 mg/kg, i.v.) decreases peripheral lymphocytes in mouse, rat, dog, and monkey (IC₅₀s = 101, 51, 58, and 98 nM, respectively). It delays or prevents the onset and severity of murine experimental autoimmune encephalomyelitis (EAE) when administered at 0.3, 1, or 3 mg/kg. It also leads to lower EAE disease scores relative to vehicle when administered after disease onset and is efficacious in a rat model of collagen-induced arthritis.

References

1. Buzard, D.J., Kim, S.H., Lopez, L., *et al.* Discovery of APD334: Design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor. *ACS Med. Chem. Lett.* **5**(12), 1313-1317 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/14/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM